PT  - JOURNAL ARTICLE
AU  - GERRIT STEFFEN MAIER
AU  - KONSTANTIN HORAS
AU  - ANDREAS ALOIS KURTH
AU  - DJORDJE LAZOVIC
AU  - JÖRN BENGT SEEGER
AU  - UWE MAUS
TI  - Prevalence of Vitamin D Deficiency in Patients with Bone Metastases and Multiple Myeloma
DP  - 2015 Nov 01
TA  - Anticancer Research
PG  - 6281--6285
VI  - 35
IP  - 11
4099  - http://ar.iiarjournals.org/content/35/11/6281.short
4100  - http://ar.iiarjournals.org/content/35/11/6281.full
SO  - Anticancer Res2015 Nov 01; 35
AB  - Background/Aim: Breast and prostate cancer are amongst the most prevalent malignancies globally and up to 40% of patients will develop metastatic disease, particularly to the skeleton. Multiple myeloma is the most common cancer to affect bone with up to 90% of patients developing bone lesions. Although several studies demonstrated that endocrine changes such as vitamin D deficiency promote secondary cancer growth in bone, relatively few have reported its prevalence. For this reason, the purpose of the present study was to evaluate the prevalence of hypovitaminosis D in patients with bone metastases and multiple myeloma. Patients and Methods: Serum 25-OH-D levels of patients with metastatic bone disease were measured on admission. Statistical analyses was performed to evaluate for possible confounders of hypo-vitaminosis D. Results: We found a widespread and alarming rate of vitamin D deficiency in patients with metastatic bone disease and multiple myeloma. Of note, patients with bone metastases due to breast cancer, prostate cancer and multiple myeloma rarely reached sufficient serum 25-OH-D levels. Conclusion: It is of utmost clinical importance to assess vitamin D levels in cancer patients, especially in those with, or at high risk of developing metastatic bone disease.